Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, ETH Zurich, Wolfgang-Pauli-Strasse 10, CH-8093 Zurich, Switzerland.
Pharmacol Ther. 2013 Sep;139(3):405-11. doi: 10.1016/j.pharmthera.2013.05.006. Epub 2013 May 24.
Metastatic melanoma is one of the most deadly forms of cancer and is poorly responsive to standard chemotherapeutics, such as Dacarbazine and Paclitaxel. Recently, the advent of Vemurafenib and Ipilimumab has broadened the spectrum of therapeutic options for advanced melanoma patients but the occurrence of resistance and of high-grade toxicities call for better and more effective treatments. This review focuses on approved and experimental therapies for metastatic melanoma. The mechanism of action and the reported efficacy data for small molecule drugs and biologics are discussed, outlining directions for future pharmaceutical research in this field.
转移性黑色素瘤是最致命的癌症形式之一，对标准化疗药物（如达卡巴嗪和紫杉醇）反应不佳。最近，威罗非尼和依匹单抗的出现拓宽了晚期黑色素瘤患者的治疗选择范围，但耐药性的发生和高等级毒性需要更好和更有效的治疗方法。本综述重点介绍转移性黑色素瘤的已批准和实验性治疗方法。讨论了小分子药物和生物制剂的作用机制和报告的疗效数据，为该领域的未来药物研究指明了方向。
